On the occasion of World Cancer Day, to be held next Saturday, February 4, IDIBAPS, together with the AECC, has organized three meetings between volu1
Some of the most common side effects of chemotherapy are fatigue, nausea and vomiting. To alleviate them, you should rest, stay hydrated and maintain1
The spin-off helmed by Aleix Prat received the award in the category of Collaborative Research in Transfer for Development for its HER2DX breast canc1
HER2DX® was highlighted in Times 'Medical Care' category, which publicizes inventions that are successfully implemented in medical practice.
Trial TILs001, which is open to patients with metastatic triple-negative breast cancer, is the first study to assess the safety and efficacy of TILs1
Treatment with trastuzumab deruxtecan, a combination of a targeted therapy with chemotherapy, increases progression-free survival of the disease and1
Aleix Prat is leading the research, which focuses on discovering new ways of diagnosing hormone receptor-positive breast cancer, as well as new thera1
The new test, called HER2DX, analyzes RNA on 27 genes to predict survival outcomes and the likelihood that patients will respond to treatment.
On Thursday, 11 November, the Spanish Cancer Association (AECC) awarded the AECC 2021 Grants for Cancer Research at an event held at the organization1
Researchers from Hospital Clínic-IDIBAPS have shown for the first time that the benefit of chemotherapy in premenopausal patients with low-risk hormo1
